The best pharmaceutical stock market is worth crushing Sinopec! The boss is worth more than Wang Jianlin

 The best pharmaceutical stock market is worth crushing Sinopec! The boss is worth more than Wang Jianlin

From the bottom of October 2003 to todays new high, in less than 17 years, the stock price of Hengrui medicine rose by 320 times. According to wind statistics, since 2000, from the bottom, Hengrui has risen 340 times. With continuous skyrocketing and new highs, the static P / E valuation of Hengrui pharmaceutical is not low, but some securities companies continue to be optimistic, and some private equity companies also say that there is still a lot of room for the future value improvement of pharmaceutical stocks.

Data shows that since 2000, Guizhou Maotai, Changchun hi tech, Hengrui medicine, Sanan photoelectric and Hengsheng electronics have achieved more than 300 times of growth, Guizhou Maotai is more than 40 times, Changchun Gaoxin is more than 390 times, and Hengrui medicine ranks third. Consumption and medicine are really big stocks.

Medicine bull stocks soared 300 times to a new high

As the value leader of A-share pharmaceutical stock market, Hengrui pharmaceutical share price keeps breaking new highs. Todays share price has reached a new high, with a market value of more than 500 billion yuan. At one time, it rose 2.6% in early trading today, and still rose 0.43% by the end of the morning. Since this year, Hengrui pharmaceutical has increased by 28.38%.

Today, Hengrui medicine has new advantages. Hengrui medicine announced today that the company announced that the subsidiary company obtained the drug registration approval document, and the two major indications of single drug treatment of second-line advanced esophageal squamous cell carcinoma, single drug treatment of carrizumab + pemetrexed + carboplatin treatment of first-line advanced or metastatic non squamous non-small cell lung cancer were approved by the State Drug Administration.

Founded in 1970, Hengrui pharmaceutical is a pharmaceutical and health enterprise engaged in pharmaceutical innovation and high-quality drug R & D, production and promotion. It is committed to the innovation and development of anti-tumor drugs, surgical drugs, endocrine therapy drugs, cardiovascular drugs and anti infective drugs, and gradually forms a brand advantage. By the end of 2019, there are more than 24000 employees worldwide.

Market value surpasses Sinopec:

The companys market value has reached 500 billion yuan. Hengrui pharmaceutical has broken through the market value list of A-share banks oil and petrochemical industry, surpassing Sinopec in market value and becoming the 10th company in market value of A-share.

Hengrui in China vs Pfizer in the United States

Hengruis share price soared, with a P / E ratio of more than 90 times based on 2019s performance, while Pfizers in the US only trades at 12 times. In terms of market value, Hengrui is about 500 billion yuan, while Pfizer is currently 131 million yuan.

In terms of all indicators in 2019 (all in RMB), Hengruis operating revenue is 23.3 billion yuan, Pfizers operating revenue is 365.9 billion yuan; Hengruis net profit is 5.3 billion yuan, Pfizers net profit is 115.2 billion yuan; research and development investment of Hengrui is 3.9 billion yuan, Pfizers 61.2 billion yuan. Hengruis winning indicator is growth, with a 5-year compound growth rate of 29%, while Pfizers is only 12%.

Private placement: the future value promotion space of pharmaceutical stocks

Yang Yong said that in recent years, the country has encouraged the research and development of innovative drugs and put them into the market. Correspondingly, the return on investment of pharmaceutical enterprises with R & D capability can be greatly improved, which will be reflected in the rise of stock price in the secondary market.

Fund continued to increase in the first quarter

Data shows that at the end of the first quarter, 861 funds held 330 million shares of Hengrui medicine, a significant increase of 56.68 million shares compared with the end of last year.

Research Report of securities companies: maintain purchase rating

For the approval documents of drug registration obtained by subsidiaries, Huaxi Securities Research Report commented and continued to maintain the purchase rating.

1. The progress of major indications is the fastest, and the advantage of carrizole continues to expand

Up to now, four domestic pd-1s have been approved for listing (see the table below), and the competition in the domestic market is gradually fierce. The current main strategy of PD-1 enterprise is to seize the clinical progress of large indications and combine drugs. The company has its own strong clinical team, so it has great advantages in subject recruitment and clinical costs, leading in large indications such as liver cancer and lung cancer. The companys anti-tumor innovative drug pipeline is rich, and carrizhu is also the largest combination of PD-1 products in China.

2. All four indications may be covered this year, leading the market

Among the four PD-1 in China, in addition to Xinda bios xindili mAb entering the medical insurance in 2019 for Hodgkins lymphoma indication, two new indications approved by Baiji Shenzhou are not eligible for medical insurance negotiation this year, and the application for listing of Xinda and Junshi new indications is expected to catch up with this years medical insurance negotiation; while the four indications approved by the companys karelizumab are Hodgkins lymphoma, liver cancer, lung cancer and esophageal cancer Or it will have the opportunity to enter the medical insurance and further expand the market leading advantage.

Sun piaoyang, the real controller of Hengrui, is a fortune surpasser of Wang Jianlin

The share price soared, and the wealth of sun piaoyang, the actual controller of Hengrui pharmaceutical, also grew. According to the latest Forbes rich list, sun piaoyangs wealth is 16 billion dollars, surpassing the former richest man Wang Jianlins 14 billion dollars.

Source: China Fund News Author: Jiang You editor in charge: Wang Xiaowu_ NF